First Phase III results for AstraZeneca and Daiichi Sankyo's TROP2-directed ADC

3 July 2023

Shares of UK pharma major AstraZeneca (LSE: AZN) fell 5.5% to £10,652 this morning, after it released new data from the TROPION-Lung01 Phase III trial of its TROP2-directed antibody drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd), which is being developed under a deal with Japan’s Daiichi Sankyo (TYO: 4568).

The study demonstrated a statistically-significant improvement for the dual primary endpoint of progression-free survival (PFS) compared to docetaxel, the current standard of care chemotherapy, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior therapy.

Analysts at Barclays and Credit Suisse said shareholders will be concerned that AstraZeneca did not declare its results “clinically meaningful” in its press release, and hoped it would be as good as Enhertu (trastuzumab deruxtecan), an already approve cancer drug -also developed with Daiichi Sankyo, which is transforming the care of some cancer patients, especially in breast cancer. The company also reported some deaths in the trial, raising safety concerns.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK